Coherus Oncology (CHRS) vs Outlook Therapeutics (OTLK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Coherus Oncology (CHRS) has outperformed Outlook Therapeutics (OTLK) over the past year, losing 39.2% versus a loss of 55.2%. Over five years, CHRS leads with a -93.7% price change compared with -98.7% for OTLK. Coherus Oncology is the larger company by market cap ($165.3 million vs $137.3 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CHRS | OTLK |
|---|---|---|
| Share price | $1.07 | $0.564 |
| Market cap | $165.32M | $137.30M |
| 1-day change | +5.94% | -4.41% |
| YTD return | -24.65% | -64.30% |
| 1-year return | -39.20% | -55.24% |
| 5-year return | -93.71% | -98.66% |
| EPS (TTM) | $-1.25 | $-0.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.62 | $2.54 |
| 52-week low | $0.974 | $0.161 |
| Distance from 52-week high | -59.10% | -77.78% |
| Analyst consensus | none | none |
| Avg. price target upside | +624.30% | +791.84% |
| Average volume | 1.16M | 13.33M |
| Shares outstanding | 154.50M | 243.45M |
| Employees | 144 | 17 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CHRS has outperformed OTLK by 16.0 percentage points over the past year.
About Coherus Oncology
CHRS stock →Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 144 employees
About Outlook Therapeutics
OTLK stock →Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 17 employees
CHRS vs OTLK FAQ
Which is bigger, Coherus Oncology or Outlook Therapeutics?
Coherus Oncology (CHRS) is larger, with a market capitalization of $165.32M compared with $137.30M for Outlook Therapeutics (OTLK).
Which stock has performed better over the past year, CHRS or OTLK?
CHRS returned -39.20% over the past 12 months, compared with -55.24% for OTLK (price return, excluding dividends). Past performance does not predict future results.
Are Coherus Oncology and Outlook Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.